{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:05:05Z","timestamp":1780315505459,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jtct.2025.12.1003","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:19:25Z","timestamp":1767629965000},"page":"586.e1-586.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Romiplostim in Treating Thrombocytopenia after Hematopoietic Stem Cell Transplantation in Pediatric Patients: A Single-Arm Clinical Trial"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-6354","authenticated-orcid":false,"given":"Zahra","family":"Karimizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Behfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atieh","family":"Karimzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirali","family":"Kalantari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynab","family":"Nikfetrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Ali","family":"Hamidieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2025.12.1003_bib0001","series-title":"The EBMT Handbook","article-title":"HCT: Historical perspective","year":"2024"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.1003_bib0002","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29177","article-title":"Reduced-intensity conditioning\u2013based hematopoietic cell transplantation for dyskeratosis congenita: single-center experience and literature review","volume":"68","author":"Bhoopalan","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.1003_bib0003","doi-asserted-by":"crossref","first-page":"e1050","DOI":"10.1097\/MPH.0000000000002374","article-title":"Fludarabine-based reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in a pediatric patient with bone marrow failure syndrome type 3","volume":"44","author":"Barhoom","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.1003_bib0004","doi-asserted-by":"crossref","first-page":"e1148","DOI":"10.1097\/MPH.0000000000002227","article-title":"Encouraging outcomes of alternate donor hematopoietic stem cell transplant in pediatric high-risk\/relapsed leukemias: a single center experience","volume":"43","author":"Sachdev","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.1003_bib0005","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/s41409-022-01726-2","article-title":"Delayed platelet recovery and mortality after allogeneic stem cell transplantation in children","volume":"57","author":"Wells","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.1003_bib0006","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.bbmt.2019.12.003","article-title":"Use of thrombopoietin receptor agonists in prolonged thrombocytopenia after hematopoietic stem cell transplantation","volume":"26","author":"Mahat","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.1003_bib0007","first-page":"106","article-title":"Thrombocytopenia after hematopoietic stem cell transplantation in pediatrics and adults: a narrative review including etiology, management, monitoring, and novel therapies","volume":"52","author":"Kalantari","year":"2025","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.1003_bib0008","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/hon.2937","article-title":"Poor survival and prediction of prolonged isolated thrombocytopenia post umbilical cord blood transplantation in patients with hematological malignancies","volume":"40","author":"Wu","year":"2022","journal-title":"Hematol Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.1003_bib0009","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.bbmt.2016.06.003","article-title":"Risk factors and impact of secondary failure of platelet recovery after allogeneic stem cell transplantation","volume":"22","author":"Akahoshi","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.12.1003_bib0010","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2147\/ITT.S463384","article-title":"Thrombopoietin receptor agonists in post-hematopoietic cell transplantation complicated by prolonged thrombocytopenia: a comprehensive review","volume":"13","author":"Elsayed","year":"2024","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.jtct.2025.12.1003_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109579","article-title":"Low-dose decitabine for refractory thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children: a pilot study","volume":"115","author":"Liu","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.1003_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11051364","article-title":"Thrombocytopenia and therapeutic strategies after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Bento","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.1003_bib0013","doi-asserted-by":"crossref","first-page":"128","DOI":"10.46989\/001c.94135","article-title":"Transfusion support in hematopoietic stem cell transplantation: a contemporary narrative review","volume":"6","author":"Adkins","year":"2024","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.jtct.2025.12.1003_bib0014","series-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","article-title":"Transfusion support","author":"Schrezenmeier","year":"2024"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.1003_bib0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/trf.12817","article-title":"Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation","volume":"55","author":"Christou","year":"2015","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.1003_bib0016","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/bbmt.2001.v7.pm11302549","article-title":"Secondary failure of platelet recovery after hematopoietic stem cell transplantation","volume":"7","author":"Bruno","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"10.1016\/j.jtct.2025.12.1003_bib0017","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3390\/diagnostics13132257","article-title":"Patient blood management after hematopoietic stem cell transplantation in a pediatric setting: starting low and going lower","volume":"13","author":"Del Fante","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.1003_bib0018","doi-asserted-by":"crossref","first-page":"866.e1","DOI":"10.1016\/j.jtct.2021.07.001","article-title":"Platelet and red blood cell transfusions and risk of acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation","volume":"27","author":"Gjaerde","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.12.1003_bib0019","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40262-016-0382-7","article-title":"Development of romiplostim for treatment of primary immune thrombocytopenia from a pharmacokinetic and pharmacodynamic perspective","volume":"55","author":"Yang","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtct.2025.12.1003_bib0020","unstructured":"Amgen Inc. Nplate (romiplostim) for injection, for subcutaneous use [prescribing information]. Silver Spring, MD: Food and Drug Administration (FDA); 2025 Feb. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125268s176lbl.pdf."},{"issue":"8","key":"10.1016\/j.jtct.2025.12.1003_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26473","article-title":"Romiplostim for therapy-related thrombocytopenia in pediatric malignancies","volume":"64","author":"Jacobson","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.1003_bib0022","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31528","article-title":"Thrombopoietin receptor agonists for thrombocytopenia in pediatric hematologic malignancies","volume":"72","author":"Marinoff","year":"2025","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.1003_bib0023","doi-asserted-by":"crossref","first-page":"E252","DOI":"10.1111\/petr.12325","article-title":"Successful treatment of post-transplant thrombocytopenia with romiplostim in a pediatric patient with X-linked chronic granulomatous disease","volume":"18","author":"Buchbinder","year":"2014","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jtct.2025.12.1003_bib0024","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12185-015-1821-1","article-title":"Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children","volume":"102","author":"Maximova","year":"2015","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.1003_bib0025","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2280872","article-title":"Romiplostim use for thrombocytopenia following allogeneic hematopoietic stem cell transplantation: a case series from a single center in Qatar","volume":"28","author":"Al-Mashdali","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.jtct.2025.12.1003_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.680411","article-title":"Off-label use of thrombopoietin receptor agonists: case series and review of the literature","volume":"11","author":"Capecchi","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.1003_bib0027","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1097\/MPH.0000000000001810","article-title":"Up-front treatment with romiplostim in children with acquired bone marrow failure: a single institutional pediatric case series","volume":"43","author":"Al-Huniti","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.1003_bib0028","doi-asserted-by":"crossref","first-page":"63","DOI":"10.15252\/emmm.201708168","article-title":"Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim","volume":"10","author":"Pecci","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jtct.2025.12.1003_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/20406207251353007","article-title":"Efficacy of therapeutic strategies on thrombocytopenia after hematopoietic stem cell transplantation-an evidence-based meta-analysis","volume":"16","author":"Hua","year":"2025","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.1003_bib0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood.2019000358","article-title":"Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1\/2 multicenter trial","volume":"135","author":"Peffault de Latour","year":"2020","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2025.12.1003_bib0031","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00277-007-0317-3","article-title":"Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis","volume":"86","author":"Garcia-Chavez","year":"2007","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.1003_bib0032","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ajh.21512","article-title":"Repeated courses of rituximab in chronic ITP: three different regimens","volume":"84","author":"Hasan","year":"2009","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.jtct.2025.12.1003_bib0033","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S2352-3026(19)30153-X","article-title":"Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial","volume":"6","author":"Lee","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.1003_bib0034","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1200931","article-title":"Eltrombopag and improved hematopoiesis in refractory aplastic anemia","volume":"367","author":"Olnes","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.1003_bib0035","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2021012589","article-title":"Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial","volume":"139","author":"Garcia-Manero","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.12.1003_bib0036","unstructured":"U.S. Department of Health and Human Services NIoHN. National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events (CTCAE). Bethesda, MD: National Cancer Institute; 2017. v 5.0. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"10.1016\/j.jtct.2025.12.1003_bib0037","series-title":"WHO Handbook for Reporting Results of Cancer Treatment","first-page":"45","year":"1979"},{"issue":"11","key":"10.1016\/j.jtct.2025.12.1003_bib0038","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.1003_bib0039","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V100.2.406","article-title":"Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse","volume":"100","author":"Lee","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.1003_bib0040","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2010-10-313908","article-title":"A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia","volume":"118","author":"Bussel","year":"2011","journal-title":"Blood"},{"issue":"10039","key":"10.1016\/j.jtct.2025.12.1003_bib0041","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0140-6736(16)00279-8","article-title":"Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"Tarantino","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.1003_bib0042","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2017-02-768036","article-title":"Bone marrow failure unresponsive to bone marrow transplant is caused by mutations in thrombopoietin","volume":"130","author":"Seo","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.1003_bib0043","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood.2019000358","article-title":"Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1\/2 multicenter trial","volume":"135","author":"Peffault de Latour","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.12.1003_bib0044","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2147\/DDDT.S299591","article-title":"A review of romiplostim mechanism of action and clinical applicability","volume":"15","author":"Bussel","year":"2021","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.1003_bib0045","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/0976500X241303618","article-title":"Clinical characteristics and risk factors for persistent thrombocytopenia among pediatric patients after bone marrow transplant in Saudi Arabia: a 3-year retrospective observational analysis from Tertiary Hospital","volume":"16","author":"Kanan","year":"2025","journal-title":"J Pharmacol Pharmacother"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.1003_bib0046","doi-asserted-by":"crossref","first-page":"497.e1","DOI":"10.1016\/j.jtct.2021.02.033","article-title":"Phase I dose-finding, safety, and tolerability trial of romiplostim to improve platelet recovery after UCB transplantation","volume":"27","author":"Christakopoulos","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.12.1003_bib0047","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1182\/blood-2019-128673","article-title":"Retrospective evaluation of the use of romiplostim after hematopoietic stem cell transplantation","volume":"134","author":"Xue","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.1003_bib0048","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/bmt.2014.299","article-title":"Hematopoietic SCT in Iranian children 1991-2012","volume":"50","author":"Hamidieh","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.1003_bib0049","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MPH.0000000000003050","article-title":"The tale of pediatric hematopoietic stem cell transplantation in Iran: an uphill battle","volume":"47","author":"Behfar","year":"2025","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.1003_bib0050","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.1016\/j.bbmt.2015.11.797","article-title":"TBI-free pediatric hematopoietic stem cell transplantation in Iran: two decades of practice","volume":"22","author":"Hamidieh","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.1003_bib0051","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s12185-024-03853-6","article-title":"Expansion effect of romiplostim on hematopoietic stem and progenitor cells versus thrombopoietin and eltrombopag","volume":"120","author":"Tezuka","year":"2024","journal-title":"Int J Hematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726000023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726000023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:08:23Z","timestamp":1780312103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726000023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666636726000023"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.1003","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Romiplostim in Treating Thrombocytopenia after Hematopoietic Stem Cell Transplantation in Pediatric Patients: A Single-Arm Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.1003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}